



MetaTech

三顧股份有限公司

Stock Code: 3224

METATECH (AP) INC. Investor Conference

2024/12/20

Disclaimer

The contents of this presentation and related information are the information collected by the company from various prior documents.

The Company is dedicated to the future development. The actual results of operations, financial condition and business achievement may differ from the forecasted information. This may be due to risk factors that are not expected to be captured by market conditions.

The future development described in this presentation is based on the judgment of market information and the development of the Group's business strategy. The Company is not responsible for alerting or updating for future development as it may be adjusted with the market trend.

簡報
大綱

1

Company Profile

2

MetaTech's Proprietary
Technological Development

3

MetaTech's BIOMED
Digitization Strategy

01. Company Profile



Governance Evaluation Score Distribution of OTC Company




Stable Corporate Governance




Revenue

Unit: NT\$ Thousands



Performance


Unit: NT\$ Thousands



Significant Year-over-Year Growth in the Biomedicine Business Unit



Number of Partner Clinics



Increase in Partner Clinics **45** Clinics
(Covering northern, central, and southern regions)

- Cell Authentication Clinics: **6+ 3**
- Regulations of Special Medical Techniques approved Institutions: **7+ 5**
- iPSC Partner Clinics: **43** Clinics

02.

**MetaTech's
Proprietary
Technological
Development**



Taiwan Regenerative Medicine Act—A New Era for Cell Therapy



June 4, 2024:
The Regenerative Medicine Act was passed, opening a new chapter for the cell therapy industry.

- Regenerative Medicine Production Regulations: Strengthening GMP standards to align the safety and quality of cell therapy products.
- MetaTech is among the first in Taiwan to obtain PIC/S GMP certification for its cell therapy production facilities, becoming one of 25 certified companies. This advances international competitiveness and industrial upgrade.

Amendment Item	Original Legislation	2024 Act on Regenerative Medicine Treatments	2024 Act on Regenerative Medicinal Products
1. Legal Compliance	Fragmented regulation, poor implementation	Act on Regenerative Medicine Treatments: Regulations on medical technology and therapeutic institutions	Act on Regenerative Medicinal Products: Regulations on the production and application of therapeutic products
2. Scope of Therapy	Undefined, narrow coverage	Includes genetic modification, stem cells, and derivatives (Article 3)	
3. Quality and Safety	No product-specific production regulations	Requires professional technical review and safety evaluation (Article 14)	Compliance with GMP and GDP standards (Article 16)
4. Human Trials	Trials require completion of all phases	Specific circumstances allow partial trial exemptions (Article 7 and 8)	Completion of Phase II clinical trials allows for conditional application for licensure (Articles 6–9)
5. Strengthened Execution	Inconsistent management and regulatory framework	Non-medical institutions are prohibited from performing regenerative medicine (Article 11)	Management of product suitability and traceability (Articles 11, 12, and 18)

MetaTech Leverages Dual Regenerative Medicine Laws to Showcase Core Competence



Regenerative Medicine Laws: Legal Highlights	Regenerative Medicine Act	Regenerative Medicine Production Regulations	MetaTech Group Advantages
<p>Cell Operation Regulations and Production Requirements Compliance with GMP and GDP Standards</p>	Article 14	Article 16	<p>Cell Therapy GMP Production Facility Equipped with four GMP operation rooms, scalable to 24 rooms, supporting CAR-T and iPSC technology production.</p>
<p>Medical Institution Standards and Professional Requirements Execution of Regenerative Medicine in Approved Medical Institutions</p>	Article 11 Article 13	Article 17	<p>Industry Leadership and Advanced Deployment Collaborated with 12 medical institutions on clinical trials and special regulatory treatments, achieving a dual-track strategy in advanced aesthetics and medical applications.</p>
<p>Accelerated Introduction of International Clinical Outcomes Direct integration of results from international Phase II trials</p>	Article 8 Paragraph 1	Article 6 Article 9	<p>International Collaboration and Rapid Market Entry Obtained multiple certifications, including PIC/S GMP and GTP. Shortened time-to-market. Promoted the commercialization of cell-based products.</p>
<p>Technical Innovation Support Regenerative medicine R&D is eligible for government incentives or subsidies.</p>	Article 10		<p>Diverse Technology Platform Integration of AI technology, digitalization, and smart factories Promoting the development of personalized regenerative medicine</p>
<p>Cell Source Management Ensuring the suitability of cell donors through testing and preservation.</p>	Article 17	Article 18	<p>Comprehensive Integration Capability Providing end-to-end services from cell source management to processing and preparation. Supporting both clinical trials and commercial applications</p>

Trump Administration Policies — Shaping the Future of Regenerative Medicine



Trump's Biomedicine Policy Advocacy

- 1. Promoting Regenerative Medicine and Biotechnology Development**

Trump Proposed and Advocated the "Right to Try Act" with [patient consent, physician approval, and qualified manufacturing], terminally ill patients are allowed to try medications not yet approved by the FDA. This initiative supports the development of cell and gene therapies while strengthening the growth of the biotech manufacturing industry, including the expansion of CDMO (Contract Development and Manufacturing Organization).
- 2. Reducing Regulation**

Advocating Reduced Regulation on the Biotech and Medical Industries, accelerating the approval process for new drugs, enabling patients to access the latest therapies more quickly. Enhancing the efficiency of medical services.
- 3. Prescription Drug Pricing Policies**

Tends to Support Drug Imports, promoting market competition to achieve the goal of price rationalization.
- 4. U.S.-China "BIOSECURE Act"**

In 2024, the United States Passed the Biosafety Act, providing a clearer regulatory framework for cell therapy.

Personalized Precision Medicine—Starting with iPSC (Induced Pluripotent Stem Cells) Banking



- 2010 (Japan): CIRA Lab established, iPSC public banking with approximately 70 lines.
- 2013 (Japan): Reprocell founded, advancing iPSC research.



2013 (South Korea): South Korean government established iPSC public banking with approximately 100 lines.




2014 (Europe): European Union established iPSC public banking with approximately 500 lines (EBiSC).



2014 (USA): CIRM established, iPSC public banking with approximately 3,000 lines

**2024 (Taiwan):
MetaTech aims to build
Taiwan's leading personalized
iPSC banking brand**

Diverse Development of iPSC Banking: A New Plan for the Next Generation of Cell Therapy




METATECH GROUP Customized Family iPSC Services

- Personalized Family Health Cell Bank
- Drug Screening Platform
- Seeds for Personalized Precision Cell Therapies
- Generational Transfer of Family Pluripotent Stem Cells

Celebrity Family: Customized storage of pluripotent stem cells




Extensive Coverage by Major Domestic and International Media



抽25c.c.血就能逆轉成「多功能幹細胞」再生器官10年後可成真！昆凌這樣做

壹新聞 | 1.8k 人追蹤 ☆ 追蹤

天王一家健康交給他 昆凌見證「iPSC」把幹細胞變成「心跳」



Cutting-Edge Stem Cell Technology Captures the Heart of Asian King – iPSC Family Stem Cell Storage Service

by All Digital Inc. November 11, 2024 1:01 AM | 3 min read | Make a Comment



讓「天王嫂」昆凌點頭將健康交給她 楊澄臻領軍再生醫療新革命

2024/11/08 18:33 壹新聞報導 / 黃亞新 綜合報導

Current Progress under the Approval of the Regulations of Special Medical Techniques



Cell-Therapy Product	Indication	2024	2025	2026
Autologous Chondrocytes	Knee Cartilage Defects	2020: Implementation began; 70 patients treated.		
Autologous Mesenchymal Stem Cells	Skin Defects	2021: Implementation began; 11 patients treated.		
Bone Marrow-Derived Stem Cells (Outsourced Cultivation)	Spinal Cord Injury	August 2024: Approval obtained, with case collection expected to start in March 2025.		

Prevalence of Indications

Cell-Therapy Product	Indication	Prevalence
Autologous Chondrocytes	Knee Cartilage Defects	In osteoarthritis patients, cartilage defects account for approximately 15%-20%, associated with aging and physical activity.
Autologous Mesenchymal Stem Cells	Skin Defects	Globally, the annual compound growth rate for skin defects is 9.5%. In Taiwan, the potential market value of autologous stem cell applications in skin defects is estimated at 20-50 billion NTD. Global prevalence is 3-10 cases per 10,000 people, often linked to severe burns and chronic ulcers.
Bone Marrow-Derived Stem Cells (Outsourced Cultivation)	Spinal Cord Injury	Globally, there are approximately 10-20 new cases per million population annually, mostly related to traffic and sports injuries

Clinical Trial Progress



Cell-Therapy Product	Indication	Phase	2024年	2025年	2026年			
Autologous Oral Epithelial Cells	Esophageal Cancer	III	Clinical Trial Ongoing			Approval Review	Inspection Registration Application	
Immune Cells (AI-Assisted Technology)	Colorectal Cancer	IND preparation	CDE Consultation	IND Submission	Clinical Trial Ongoing		Approval Review	
Allogeneic Chondrocytes	Cartilage Defects	IND preparation	IND Submission		Clinical Trial Ongoing			
Allogeneic Stem Cells	Kidney Injury	IND preparation	CDE Consultation	IND Submission	Clinical Trial Ongoing		Approval Review	
Allogeneic Stem Cells	Underactive bladder	IND preparation	Complete Preclinical Testing	CDE Consultation	IND Submission	Clinical Trial Ongoing		Approval Review

Prevalence of Indications

Cell-Therapy Product	Indication	Prevalence
Autologous Oral Epithelial Cells	Esophageal Cancer	The prevalence of esophageal cancer in East Asia is 2–4 cases per 10,000 people; globally, 1–2 cases per 10,000 people.
Immune Cells (AI-Assisted Technology)	Colorectal Cancer	Annually, there are 19 new cases per 100,000 people worldwide, with Asia and Taiwan being high-incidence areas.
Allogeneic Chondrocytes	Cartilage Defects	In osteoarthritis patients, cartilage defects account for approximately 15%–20%, associated with aging and physical activity.
Allogeneic Stem Cells	Kidney Injury	Kidney injuries in hospitalized patients occur at a rate of 20%–30%, with ICU cases reaching up to 50%.
Allogeneic Stem Cells	Underactive bladder	Prevalence rates range from 9%–43%, often observed in middle-aged individuals, neurological diseases, or aging-related muscle loss, more common in women.

03.

**MetaTech
BIOMED
Digitization
Strategy**



Digital Twin



Physical space

Physical factory superintendent



Virtual space

Digital factory superintendent

Sensing and Operational Data

Information, Procedures, Results and Decisions



Visualization



Analysis/Diagnosis



Evaluation and Prediction/What if Analysis



Optimal Decision Making Support



Total Patent Applications **33** cases

(27 invention patents, 6 utility patents)

- Invention Patents **27** cases
- Utility Patents **6** cases
- Approved Patents **1** cases

Taiwan
invention patent





MetaTech

三顧股份有限公司

Stock Code: 3224

METATECH (AP) INC. Investor Conference

THANK
YOU

Listening Your Feedback is
Highly Appreciated

2024/12/20